Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | BCR | P11274 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.57 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 3/20 | 0.55 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | STK10 | O94804 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | CDK11B | P21127 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236572 | 0.88 | KIT (0.63) | ABL1KDRFGFR1BCRSRC | |
| SCHEMBL16254749 | 0.86 | MKNK2 (0.60) | ABL1KDRFGFR1BCRSRC | |
| SCHEMBL28054441 | 0.85 | ABL1 (0.69) | ABL1SRCHTTKIT | |
| SCHEMBL20568827 | 0.84 | EPHA2 (0.63) | ABL1KDREPHA2HTTMAP3K7 | |
| SCHEMBL1420613 | 0.84 | CHRM4 (0.67) | ABL1KDREPHA2HTTMAP3K7 | |
| SCHEMBL1420251 | 0.83 | EPHA2 (0.62) | ABL1KDREPHA2HTTMAP3K7 | |
| SCHEMBL2371128 | 0.83 | KIT (0.64) | ABL1KDREPHA2HTTMAP3K7 | |
| SCHEMBL22772360 | 0.82 | ABL1 (0.85) | ABL1KDRFGFR1BCRSRC | |
| SCHEMBL16254807 | 0.81 | SRC (0.68) | ABL1KDRFGFR1BCRSRC | |
| SCHEMBL15847505 | 0.80 | ABL1 (0.69) | ABL1KDRFGFR1SRCKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917214-B1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-08-28 | — | — | EP | disclosed |
| US-9604980-B2 | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-20150299192-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-10-22 | — | — | US | disclosed |
| CN-104870446-A | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2015-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299192-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, MAP3K8, MAP3K1 | ABL1 35/4885KDR 247/4885FGFR1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.